Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration.

Moon SW, Oh J, Yu HG, Cho HY, Song SJ.

J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):556-9. doi: 10.1089/jop.2012.0148. Epub 2013 Mar 12.

PMID:
23480269
2.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.

Ophthalmologica. 2009;223(6):370-5. doi: 10.1159/000227783. Epub 2009 Jul 8.

PMID:
19590252
3.

Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.

Diabetic Retinopathy Clinical Research Network*.

JAMA Ophthalmol. 2013 Mar;131(3):283-93. doi: 10.1001/jamaophthalmol.2013.2015.

4.

Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.

Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW Jr.

Retina. 2009 Sep;29(8):1067-73. doi: 10.1097/IAE.0b013e3181b1bb06.

PMID:
19696701
5.

Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T.

JAMA Ophthalmol. 2014 Nov;132(11):1317-26. doi: 10.1001/jamaophthalmol.2014.2333. Review.

PMID:
25058694
6.

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.

Am J Ophthalmol. 2012 Jul;154(1):125-36. doi: 10.1016/j.ajo.2012.01.010. Epub 2012 Apr 1.

PMID:
22465368
7.

Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab.

Patel KH, Chow CC, Rathod R, Mieler WF, Lim JI, Ulanski LJ 2nd, Leiderman YI, Arun V, Chau FY.

Eye (Lond). 2013 May;27(5):663-7; quiz 668. doi: 10.1038/eye.2013.31. Epub 2013 Apr 5.

8.

Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration.

Olson JM, Scott IU, Kerchner DL, Kunselman AR.

Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):455-9. doi: 10.3928/23258160-20130909-06.

PMID:
24044707
9.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.

10.

Can intravitreal ranibizumab alter retrobulbar circulation in eyes with age-related macular degeneration?

Yuksel K, Altinkaynak H, Kina A, Kara N, Yazici AT, Demirok A.

J Ocul Pharmacol Ther. 2013 Oct;29(8):723-7. doi: 10.1089/jop.2013.0051. Epub 2013 Jul 5.

PMID:
23829173
11.

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.

Ophthalmology. 2009 Sep;116(9):1731-9. doi: 10.1016/j.ophtha.2009.05.024. Epub 2009 Jul 29.

PMID:
19643495
12.

The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.

Aslankurt M, Aslan L, Aksoy A, Erden B, Cekiç O.

Eur J Ophthalmol. 2013 Jul-Aug;23(4):553-7. doi: 10.5301/ejo.5000268. Epub 2013 Mar 20.

13.

Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.

Ueta T, Noda Y, Toyama T, Yamaguchi T, Amano S.

Ophthalmology. 2014 Nov;121(11):2193-203.e1-7. doi: 10.1016/j.ophtha.2014.05.022. Epub 2014 Jul 12. Review.

PMID:
25023760
14.

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.

Cunningham ET Jr, Feiner L, Chung C, Tuomi L, Ehrlich JS.

Ophthalmology. 2011 Dec;118(12):2447-52. doi: 10.1016/j.ophtha.2011.05.026. Epub 2011 Aug 27.

PMID:
21872935
15.

Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration.

Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A, Mochimaru H, Yuki K, Sasaki M, Tsubota K, Ozawa Y.

Br J Ophthalmol. 2014 Sep;98(9):1186-91. doi: 10.1136/bjophthalmol-2013-304670. Epub 2014 Apr 7.

16.

Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.

Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, Kim JW.

Am J Ophthalmol. 2015 Feb;159(2):285-92.e1. doi: 10.1016/j.ajo.2014.10.035. Epub 2014 Nov 5.

PMID:
25447115
17.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
18.

Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.

Csaky KG, Dugel PU, Pierce AJ, Fries MA, Kelly DS, Danis RP, Wurzelmann JI, Xu CF, Hossain M, Trivedi T.

Ophthalmology. 2015 Mar;122(3):579-88. doi: 10.1016/j.ophtha.2014.09.036. Epub 2014 Nov 26.

PMID:
25432081
19.

Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.

Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, Geyer O.

Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1435-40. doi: 10.1007/s00417-012-1981-0. Epub 2012 Mar 21.

PMID:
22434210
20.

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Spielberg L, Leys A.

Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6. Epub 2010 Mar 4.

PMID:
20204659
Items per page

Supplemental Content

Write to the Help Desk